NASDAQ · NVAX

Novavax Inc.

$7.46 -$0.37 (-4.66%) 1D After hours

Key Metrics

$1.23B
Market cap
P/E · TTM
$596.34M
Revenue · TTM
−$87.84M
Net income
EPS · TTM $-0.49
Dividend yield
Free cash flow
Beta · 1Y 2.01
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Feb 26 high, the share price fell 33%.

    Peak close $11.19 on Feb 26; trough close $7.46 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -33%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 6
    The stock moved +15.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6
  • Feb 26
    The stock moved +17.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.23B
Enterprise value$727.42M
Shares outstanding164.4M
52-wk range$6.20 – $11.97
Avg volume · 20D6.4M
Net cash $499.29M
Book value / share$-0.81
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Novavax Inc.
IPO dateDec 5, 1995
Employees749

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.06
P/FCF
EV/EBITDA
EV/Sales1.22
Graham №

Profitability

Gross
Operating -14.5%
Net -14.7%
FCF
ROE / ROIC 22.9% · 13.6%

Financial Health

Current ratio2.48
Quick ratio2.45
Debt / equity-2.01
Debt / EBITDA
Net cash $499.29M
Working capital$508.36M

Cash Flow · TTM

Operating CF −$91.56M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-4.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings